Temozolomide and whole brain radiotherapy for leptomeningeal metastases from non-small cell lung cancer
10.3760/cma.j.issn.1671-8925.2018.06.006
- VernacularTitle:替莫唑胺联合全脑放疗治疗非小细胞肺癌脑膜转移癌疗效初探
- Author:
Junjie ZHEN
1
;
Weiping HONG
;
Yanying YANG
;
Changguo SHAN
;
Mingyao LAI
;
Lichao WANG
;
Linbo CAI
Author Information
1. 广东三九脑科医院肿瘤综合治疗中心
- Keywords:
Leptomeningeal metastases;
Non-small cell lung cancer;
Temozolomide;
Whole brain radiotherapy
- From:
Chinese Journal of Neuromedicine
2018;17(6):570-574
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy oftemozolomide (TMZ) and whole brain radiotherapy (WBRT) in the treatment of leptomeningeal metastases (LM) from non-small cell lung cancer (NSCLC).Methods The clinical data were retrospectively analyzed of the 19 patients with LM from NSCLC who had been treated from October 2007 to June 2016 at Guangdong Sanjiu Brain Hospital.Of them,10 were treated by a combination of TMZ+WBRT,and 9 by other therapies.The survival rate was determined by the Kaplan-Meier method and analyzed using the log-rank test.Results After treatment for 2 weeks,the illness was alleviated in 8,stable in 2 and progressive in 0 of the 10 patients receiving TMZ+WBRT,yielding a remission rate of 80％;the illness was alleviated in 5,stable in 3 and progressive in one of the 9 patients receiving other therapies,yielding a remission rate of 55.6％.The median overall survival was 8 months,the survival rate was 56.3％ at 6 months and 33.8％ at one year for those receiving TMZ+WBRT;the median overall survival was 7 months,the survival rate was 55.6％ at 6 months and 14.8％ at one year for those receiving other therapies.Conclusion Temozolomide and whole brain radiotherapy may prolong the survival time and improve the prognosis of patients with LM from NSCLC.
